Ascend Advanced Therapies

Quality manufacturing capacity for developers of gene and cell therapies

First Investment: 2023

Biotech and pharmaceutical companies developing innovative gene and cell therapies no longer need to build an in-house capacity to manufacture these therapies. Ascend offers flexible chemistry, manufacturing, and controls (CMC) services for companies working in gene therapy, with an initial focus on Adeno-associated virus (AAV) vectors.

News & Insights

Ascend partners with industry to drive down gene therapy cost for better patient access

In The Media

Financial Times

UK biotech start-up raises $130mn to solve capacity bottleneck

Ascend Advanced Therapies

Explore Companies

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery